Detalhe da pesquisa
1.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
J Pharmacol Exp Ther
; 374(1): 211-222, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32345620
2.
INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
J Pharmacol Exp Ther
; 364(1): 120-130, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127109
3.
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Blood
; 115(17): 3520-30, 2010 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-20197554
4.
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.
J Med Chem
; 65(22): 15433-15442, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356320
5.
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Cancer Discov
; 12(6): 1482-1499, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254416
6.
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.
Cancer Discov
; 11(12): 3126-3141, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34193440
7.
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
J Med Chem
; 64(15): 10666-10679, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269576
8.
Characterization of human cancer xenografts in humanized mice.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32217760
9.
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Front Oncol
; 10: 598477, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33425754
10.
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
PLoS One
; 15(4): e0231877, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315352
11.
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.
Blood Adv
; 3(7): 1061-1072, 2019 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30944098
12.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Blood Adv
; 3(22): 3503-3514, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725895
13.
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Cancer Res
; 79(1): 171-182, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413412
14.
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
ACS Med Chem Lett
; 10(11): 1554-1560, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31749910
15.
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
PLoS One
; 13(6): e0199108, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29927999
16.
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Mol Cancer Ther
; 5(1): 160-9, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16432175
17.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
ACS Med Chem Lett
; 8(5): 486-491, 2017 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28523098
18.
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
J Med Chem
; 48(4): 909-12, 2005 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15715460
19.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
J Immunother Cancer
; 2: 3, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24829760
20.
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
Clin Cancer Res
; 17(22): 7127-38, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21918175